Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EBT (2016 - 2025)

Marimed has reported EBT over the past 15 years, most recently at -$7.3 million for Q4 2025.

  • Quarterly EBT fell 120.99% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.7 million through Dec 2025, down 165.23% year-over-year, with the annual reading at -$10.9 million for FY2025, 154.32% down from the prior year.
  • EBT was -$7.3 million for Q4 2025 at Marimed, down from -$182000.0 in the prior quarter.
  • Over five years, EBT peaked at $11.4 million in Q2 2021 and troughed at -$9.6 million in Q4 2023.
  • The 5-year median for EBT is $583000.0 (2021), against an average of $1.1 million.
  • Year-over-year, EBT skyrocketed 1099.1% in 2021 and then crashed 750.5% in 2025.
  • A 5-year view of EBT shows it stood at $768000.0 in 2021, then skyrocketed by 258.72% to $2.8 million in 2022, then tumbled by 449.55% to -$9.6 million in 2023, then skyrocketed by 65.57% to -$3.3 million in 2024, then plummeted by 120.99% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBT are -$7.3 million (Q4 2025), -$182000.0 (Q3 2025), and -$579000.0 (Q2 2025).